MAP2K7 and lung cancer: In lung cancer, MEK inhibition was correlated with the activation of EGFR and stimulation of its specific RTK (receptor tyrosine kinases) receptor that has the further capacity to induce a transient inhibition of ERK phosphorylation in BRAF non-V600E, but not BRAF V600E, mutant cells [55].